行情

ALBO

ALBO

Albireo Pharma
NASDAQ

实时行情|Nasdaq Last Sale

20.24
-0.76
-3.62%
已收盘, 16:00 12/13 EST
开盘
20.81
昨收
21.00
最高
21.41
最低
19.89
成交量
4.44万
成交额
--
52周最高
38.69
52周最低
16.13
市值
2.57亿
市盈率(TTM)
-3.4982
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ALBO 新闻

  • 工行与阿里巴巴、蚂蚁金服达成金融科技伙伴关系
  • 新浪财经.1小时前
  • 消息称PSA与菲亚特克莱斯勒合并计划获法国政府支持
  • 新浪财经.1小时前
  • 巴拿马自主经营运河20周年 财政贡献近18亿美元
  • 中国新闻网.2小时前
  • 沪指高开高走 美财长称未将美元武器化
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

ALBO 简况

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).
展开

Webull提供Albireo Pharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。